Phase I Study of Lenvatinib and Capecitabine with External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma

Rutika Mehta, Jessica Frakes, Jongphil Kim, Andrew Nixon, Yingmiao Liu, Lauren Howard, Maria E Martinez Jimenez, Estrella Carballido, Iman Imanirad, Julian Sanchez, Sophie Dessureault, Hao Xie, Seth Felder, Ibrahim Sahin, Sarah Hoffe, Mokenge Malafa, Richard Kim, Rutika Mehta, Jessica Frakes, Jongphil Kim, Andrew Nixon, Yingmiao Liu, Lauren Howard, Maria E Martinez Jimenez, Estrella Carballido, Iman Imanirad, Julian Sanchez, Sophie Dessureault, Hao Xie, Seth Felder, Ibrahim Sahin, Sarah Hoffe, Mokenge Malafa, Richard Kim

Abstract

Background: Neoadjuvant chemoradiation with fluoropyrimidine followed by surgery and adjuvant chemotherapy has been the standard treatment of locally advanced stages II and III rectal cancer for many years. There is a high risk for disease recurrence; therefore, optimizing chemoradiation strategies remains an unmet need. Based on a few studies, there is evidence of the synergistic effect of VEGF/PDGFR blockade with radiation.

Methods: In this phase I, dose-escalation and dose-expansion study, we studied 3 different dose levels of lenvatinib in combination with capecitabine-based chemoradiation for locally advanced rectal cancer.

Results: A total of 20 patients were enrolled, and 19 were eligible for assessment of efficacy. The combination was well tolerated, with an MTD of 24 mg lenvatinib. The downstaging rate for the cohort and the pCR was 84.2% and 37.8%, respectively. Blood-based protein biomarkers TSP-2, VEGF-R3, and VEGF correlated with NAR score and were also differentially expressed between response categories. The NAR, or neoadjuvant rectal score, encompasses cT clinical tumor stage, pT pathological tumor stage, and pN pathological nodal stage and provides a continuous variable for evaluating clinical trial outcomes.

Conclusion: The combination of lenvatinib with capecitabine and radiation in locally advanced rectal cancer was found to be safe and tolerable, and potential blood-based biomarkers were identified.

Clinical trial registration: NCT02935309.

Keywords: lenvatanib; radiation; rectal cancer.

© The Author(s) 2022. Published by Oxford University Press.

Figures

Figure 1.
Figure 1.
Baseline levels of three markers significantly differ across outcome groups.

References

    1. Kim R, Prithviraj GK, Shridhar R, et al. . Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma. Radiother Oncol. 2016;118(2):382-386.
    1. von Moos R, Koeberle D, Schacher S, et al. ; Swiss Group for Clinical Cancer Research (SAKK). Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: a phase I/II trial (SAKK 41/08). Eur J Cancer. 2018;89:82-89.
    1. Glynne-Jones R, Glynne-Jones S.. The concept and use of the neoadjuvant rectal score as a composite endpoint in rectal cancer. Lancet Oncol. 2021;22(7):e314-e326.
    1. Bosset JF, Collette L, Calais G, et al. ; EORTC Radiotherapy Group Trial 22921. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355(11):1114-1123.
    1. Deng Y, Chi P, Lan P, et al. . Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: initial results of the Chinese FOWARC multicenter, open-label, randomized three-arm phase III trial. J Clin Oncol. 2016;34(27):3300-3307.
    1. Rödel C, Graeven U, Fietkau R, et al. ; German Rectal Cancer Study Group. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015;16(8):979-989.
    1. Aschele C, Cionini L, Lonardi S, et al. . Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011;29(20):2773-2780.
    1. Gérard JP, Azria D, Gourgou-Bourgade S, et al. . Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol. 2010;28(10):1638-1644.
    1. O’Connell MJ, Colangelo LH, Beart RW, et al. . Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol. 2014;32(18):1927-1934.
    1. Schmoll H-J, Haustermans K, Price TJ, et al. . Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine +/- oxaliplatin in locally advanced rectal cancer: Final results of PETACC-6. J Clin Oncol. 2018;36(15_suppl):3500-3500.
    1. Allegra CJ, Yothers G, O’Connell MJ, et al. . Neoadjuvant 5-FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: a phase III randomized clinical trial. J Natl Cancer Inst. 2015;107(11):djv 248.
    1. Sebag-Montefiore D, Adams R, Gollins S, et al. . ARISTOTLE: a phase III trial comparing concurrent capecitabine with capecitabine and irinotecan (Ir) chemoradiation as preoperative treatment for MRI-defined locally advanced rectal cancer (LARC). J Clin Oncol. 2020;38(15_suppl):4101-4101.
    1. Dewdney A, Cunningham D, Tabernero J, et al. . Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol. 2012;30(14):1620-1627.
    1. Helbling D, Bodoky G, Gautschi O, et al. . Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07. Ann Oncol. 2013;24(3):718-725.
    1. Landry JC, Feng Y, Prabhu RS, et al. . Phase II trial of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: 5-year clinical outcomes ECOG-ACRIN cancer research group E3204. Oncologist. 2015;20(6):615-616.
    1. Salazar R, Capdevila J, Laquente B, et al. . A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features. BMC Cancer. 2015;15:60.
    1. Bornstein P, Armstrong LC, Hankenson KD, Kyriakides TR, Yang Z.. Thrombospondin 2, a matricellular protein with diverse functions. Matrix Biol. 2000;19(7):557-568.
    1. Wachsberger P, Burd R, Dicker AP.. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res. 2003;9(6):1957-1971.
    1. George TJ, Yothers G, Hong TS, et al. . NRG-GI002: a phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)—First experimental arm (EA) initial results. J Clin Oncol. 2019;37(15_suppl):3505-3505.
    1. Rahma OE, Yothers G, Hong TS, et al. . NRG-GI002: a phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)—Pembrolizumab experimental arm (EA) primary results. J Clin Oncol. 2021;39(3_suppl):8.
    1. Kasi PM, Sawyer S, Guilford J, et al. . A multicenter study to evaluate the impact of circulating tumor DNA guided therapy (BESPOKE) in patients with stage II and III colorectal cancer. Ann Oncol. 2020;31(4):S459.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa